Literature DB >> 28586030

Expression of the EP300, TP53 and BAX genes in colorectal cancer: Correlations with clinicopathological parameters and survival.

Anna E Kowalczyk1, Bartlomiej E Krazinski1, Janusz Godlewski1, Jolanta Kiewisz1, Przemyslaw Kwiatkowski1, Agnieszka Sliwinska-Jewsiewicka1, Jacek Kiezun1, Marian Sulik2, Zbigniew Kmiec1.   

Abstract

E1A binding protein P300 (EP300), tumor protein P53 (TP53) and BCL2 associated X, apoptosis regulator (BAX) genes encode proteins which cooperate to regulate important cellular processes. The present study aimed to determine the expression levels of EP300, TP53 and BAX in colorectal cancer (CRC) and to investigate their prognostic value and association with the progression of CRC. Tumor and matched unchanged colorectal tissues were collected from 121 CRC patients. Quantitative polymerase chain reaction and immunohistochemistry were used to assess the mRNA and protein levels of the studied genes. Altered expression of the studied genes in CRC tissues was observed at both the mRNA and protein levels. The depth of invasion was associated with TP53 mRNA levels and was correlated negatively with BAX mRNA expression. Moreover, a relationship between tumor location and BAX mRNA content was noted. BAX immunoreactivity was correlated positively with the intensity of p300 immunostaining and was associated with lymph node involvement and tumor-node-metastasis (TNM) disease stage. Univariate regression analysis revealed that overexpression of p53 and BAX in CRC tissues was associated with poor patient outcome. In conclusion, dysregulation of the expression of the studied genes was found to contribute to CRC pathogenesis. The association between p300 and BAX levels suggests the existence of an interdependent regulatory mechanism of their expression. Moreover, BAX expression may be regulated alternatively, in a p53-independent manner, since the lack of correlations between expression of these factors was observed.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28586030     DOI: 10.3892/or.2017.5687

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Genomics of Tumor Origin and Characteristics for Adenocarcinoma and Malignant Pleural Mesothelioma: A Case Report.

Authors:  Katsuo Usuda; Yo Niida; Masahito Ishikawa; Shun Iwai; Aika Yamagata; Yoshihito Iijima; Nozomu Motono; Sohsuke Yamada; Hidetaka Uramoto
Journal:  Front Oncol       Date:  2022-05-19       Impact factor: 5.738

2.  In silico analysis reveals EP300 as a panCancer inhibitor of anti-tumor immune response via metabolic modulation.

Authors:  Rosemarie Krupar; Christian Watermann; Christian Idel; Julika Ribbat-Idel; Anne Offermann; Helen Pasternack; Jutta Kirfel; Andrew G Sikora; Sven Perner
Journal:  Sci Rep       Date:  2020-06-10       Impact factor: 4.379

3.  Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.

Authors:  Yan Zhuang; Hailong Wang; Da Jiang; Ying Li; Lixia Feng; Caijuan Tian; Mingyu Pu; Xiaowei Wang; Jiangyan Zhang; Yuanjing Hu; Pengfei Liu
Journal:  BMC Cancer       Date:  2021-04-09       Impact factor: 4.430

4.  Galanin Receptors (GalR1, GalR2, and GalR3) Expression in Colorectal Cancer Tissue and Correlations to the Overall Survival and Poor Prognosis of CRC Patients.

Authors:  Jacek Kiezun; Janusz Godlewski; Bartlomiej E Krazinski; Zygmunt Kozielec; Zbigniew Kmiec
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

Review 5.  The role of epigenetic modifications in Colorectal Cancer Metastasis.

Authors:  Riya Su; Xinlin Wu; Liang Tao; Changshan Wang
Journal:  Clin Exp Metastasis       Date:  2022-04-16       Impact factor: 4.510

6.  Identification of prognostic biomarkers for malignant melanoma using microarray datasets.

Authors:  Guanyu Lin; Guoqian Yin; Yuyong Yan; Bojie Lin
Journal:  Oncol Lett       Date:  2019-09-24       Impact factor: 2.967

7.  Integrated Analysis to Study the Relationship between Tumor-Associated Selenoproteins: Focus on Prostate Cancer.

Authors:  Francesca Capone; Andrea Polo; Angela Sorice; Alfredo Budillon; Susan Costantini
Journal:  Int J Mol Sci       Date:  2020-09-13       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.